Neurological clinical trials which run in highly controlled and not “real-world” environments often fail to deliver data with sufficient statistical power to determine the efficacy of treatment and require participants to be evaluated in trial sites. Our easy-to-use, pre-configured video- and sensor-based, in-home platform passively, ambiently, and continuously collects objective, high-quality, real-world data (RWD) on motor and functional performance. In addition, RWD from rich contextual information about activities of daily living (ADL) and quality of life (QoL) is available. Our proprietary AI algorithm extracts digital biomarkers with superior signal-to-noise ratio and greater statistical power. This “digital phenotyping” is being trained and validated with a major academic medical center in the US, with a 30,000 patient data set. Our platform can be used for various neurological conditions including MS, Parkinson’s, Huntington’s and Gaucher’s.
Michael Davies, CEO & Cofounder - email@example.com
Mansa Shroff, Head of Partnerships